These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11921321)

  • 1. Statistical determination of cost-effectiveness frontier based on net health benefits.
    Laska EM; Meisner M; Siegel C; Wanderling J
    Health Econ; 2002 Apr; 11(3):249-64. PubMed ID: 11921321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical cost-effectiveness analysis of two treatments based on net health benefits.
    Laska EM; Meisner M; Siegel C; Wanderling J
    Stat Med; 2001 Apr; 20(8):1279-302. PubMed ID: 11304742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The familywise error rate of a simultaneous confidence band for the incremental net health benefit.
    Meisner M; Laska EM; Siegel C; Wanderling J
    Health Econ; 2002 Apr; 11(3):275-80. PubMed ID: 11921323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fieller's method and net health benefits.
    Heitjan DF
    Health Econ; 2000 Jun; 9(4):327-35. PubMed ID: 10862076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric statistical methods for cost-effectiveness analyses.
    Dinh P; Zhou XH
    Biometrics; 2006 Jun; 62(2):576-88. PubMed ID: 16918923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review.
    Sevy S; Visweswaraiah H; Mentschel C; Leucht S; Schooler NR
    J Clin Psychiatry; 2004 Jun; 65(6):756-65. PubMed ID: 15291652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 12. Statistical methods for cost-effectiveness analyses.
    Siegel C; Laska E; Meisner M
    Control Clin Trials; 1996 Oct; 17(5):387-406. PubMed ID: 8932972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A note on confidence intervals in cost-effectiveness analysis.
    Tambour M; Zethraeus N; Johannesson M
    Int J Technol Assess Health Care; 1998; 14(3):467-71. PubMed ID: 9780533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies.
    Davis SM; Koch GG; Davis CE; LaVange LM
    Schizophr Bull; 2003; 29(1):73-80. PubMed ID: 12908662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
    Rosenheck RA; Lieberman JA
    J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.
    Claxton K
    J Health Econ; 1999 Jun; 18(3):341-64. PubMed ID: 10537899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
    Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
    Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.